Search Results - "Puig, J.A."

Melanoma in Children, Adolescents, and Young Adults: The Spanish Cohort of the MELCAYA Consortium by Patricio da Silva-Junior, R.M., Ficapal, J., Potrony, M., Torres, T., Gil, M.E., Bague, J., Mateu, J., Crespi-Payeras, F., Podlipnik, S., Puig, J.A., Aguilera, P., Carrera, C., Alòs, L., Malvehy, J., Puig, S.

Get full text

Benefits of oral Polypodium Leucotomos extract in MM high-risk patients by Aguilera, P., Carrera, C., Puig-Butille, J.A., Badenas, C., Lecha, M., González, S., Malvehy, J., Puig, S.

“…Background  UV radiation and the presence of melanocytic nevi are the main risk factors of sporadic melanoma (MM). Protection of skin by an oral…”
Get full text

POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families by Potrony, M., Puig‐Butille, J.A., Ribera‐Sola, M., Iyer, V., Robles‐Espinoza, C.D., Aguilera, P., Carrera, C., Malvehy, J., Badenas, C., Landi, M.T., Adams, D.J., Puig, S.

“…Summary Background Germline mutations in telomere‐related genes such as POT1 and TERT predispose individuals to familial melanoma. Objectives To evaluate the…”
Get full text

Mutational status of naevus-associated melanomas by Shitara, D., Tell-Martí, G., Badenas, C., Enokihara, M.M.S.S., Alós, L., Larque, A.B., Michalany, N., Puig-Butille, J.A., Carrera, C., Malvehy, J., Puig, S., Bagatin, E.

“…Summary Background The origin of melanoma has always been a debated subject, as well as the role of adjacent melanocytic naevi. Epidemiological and…”
Get full text

Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF by Mangas, C., Potrony, M., Mainetti, C., Bianchi, E., Carrozza Merlani, P., Mancarella Eberhardt, A., Maspoli-Postizzi, E., Marazza, G., Marcollo-Pini, A., Pelloni, F., Sessa, C., Simona, B., Puig-Butillé, J.A., Badenas, C., Puig, S.

“…Summary Background Nearly 10% of all cases of cutaneous melanoma (CM) occur in patients with a personal or family history of the disease. Objectives To obtain…”
Get full text

Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma by Pozzobon, F.C., Puig-Butillé, J.A., González-Alvarez, T., Carrera, C., Aguilera, P., Alos, L., Badenas, C., Grichnik, J.M., Malvehy, J., Puig, S.

“…Summary Background The identification of BRAF mutations in melanoma led to the development and implementation of new and effective therapies. Few clinical and…”
Get full text

Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population by Puig-Butillé, J.A., Carrera, C., Kumar, R., Garcia-Casado, Z., Badenas, C., Aguilera, P., Malvehy, J., Nagore, E., Puig, S.

“…Summary Background Cutaneous melanoma tumour is classified into clinicohistopathological subtypes that may be associated with different genetic and host…”
Get full text

Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry: reply from the authors by Shitara, D., Tell-Martí, G., Badenas, C., Enokihara, M.M.S.S., Alós, L., Larque, A.B., Michalany, N., Puig-Butille, J.A., Carrera, C., Malvehy, J., Puig, S., Bagatin, E.

Get full text

Genetic variations of patients with familial or multiple melanoma in Southern Brazil by Grazziotin, T.C., Rey, M.C.W., Bica, C.G., Pinto, L.A., Bonamigo, R.R., Puig-Butille, J.A., Cuellar, F., Puig, S.

“…Background  Patients with familial melanoma or multiple primary melanoma represent a high‐risk population to hereditary melanoma. Mutations in susceptibility…”
Get full text

1268P Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC by De Herreros, M. Garcia, Muñoz, S., Teixido, C., Díez-Guardia, V., Arcocha, A., Pipinikas, C., Martínez, D., Castillo, S., Reyes, R., Melia, M. Riudavets, Auclin, E., Marin, E., Howarth, K., Martinez, D., Puig, J.A., Prat, A., Aransay, N. Reguart, Viñolas, N., Mezquita, L.

Get full text

CDKN2A mutations in melanoma families from Uruguay by Borges, A.L., Cuéllar, F., Puig-Butillé, J.A., Scarone, M., Delgado, L., Badenas, C., Milà, M., Malvehy, J., Barquet, V., Núñez, J., Laporte, M., Fernández, G., Levrero, P., Martínez-Asuaga, M., Puig, S.

“…Summary Background  Familial melanoma, a cluster of several cases within a single family, accounts for approximately 10% of cases of melanoma. Hereditary…”
Get full text

601 Common mechanisms and signaling pathways in fibroblasts of cancer-prone genodermatoses by Díaz, F., León, C., García-García, F., Chacón-Solano, E., Larcher, F., Carbonell, J., Puig, J.A., Puig, S., Dopazo, J., del Río, M.

Get full text

Mutation of the tumour suppressor p33ING1b is rare in melanoma by Stark, M., Puig-Butille, J.A., Walker, G., Badenas, C., Malvehy, J., Hayward, N., Puig, S.

“…Summary Background  The p33ING1b gene is involved in the p53‐dependent response to DNA damage following exposure to ultraviolet radiation, and has recently…”
Get full text

140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial by Guarneri, V., Dieci, M.V., Griguolo, G., Pare Brunet, L., Marin, M., Miglietta, F., Bottosso, M., Giorgi, C.A., Blasco, P., Castillo, O., Galván, P., Jares, P., Puig-butille, J.A., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Conte, P.F., Prat, A.

Get full text

263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) by Rodriguez Hernandez, A., Martinez Saez, O., Brasó-Maristany, F., Pastor, B., Potrony, M., Moreno, L., Grau, E., Puig-Butille, J.A., Sánchez, A., Schettini, F., Conte, B., Chic, N., Vidal Losada, M.J., Munoz, M., Balaguer, F., Prat, A., Adamo, B.

Get full text

25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial by Brasó-Maristany, F., Martinez Saez, O., Pare Brunet, L., Marín-Aguilera, M., Conte, P.F., Jares, P., Guarneri, V., Pascual, T., Puig-Butille, J.A., Vivancos, A., Parker, J., Villagrasa Gonzalez, P., Tolaney, S.M., Carey, L.A., Perou, C.M., Prat, A.

Get full text

147P Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain by Rodriguez Hernandez, A., Braso Maristany, F., Pastor, B., Potrony, M., Moreno, L., Grau, E., Puig-Butille, J.A., Martinez Saez, O., Conte, B., Chic, N., Vidal Losada, M.J., Munoz, M., Balaguer, F., Prat, A., Adamo, B.

Get full text

Evaluation of EGFR mutation testing in plasma from non-small cell lung cancer (NSCLC) patients by De Aledo-Castillo, J.M. González, Victoria, I., Arcocha, A., Reguart, N., Porto, R. Molina, Puig-Butillé, J.A.

Get full text

血液中特定 DNA 片段的水平及其与黑色素瘤分期的相关性 by Calbet‐Llopart, N., Potrony, M., Tell‐Martí, G., Carrera, C., Barreiro, A., Aguilera, P., Podlipnik, S., Puig, S., Malvehy, J., Puig‐Butillé, J.A.

Get full text

1366P - Evaluating polygenic risk score prediction model for melanoma prognosis by Potrony, M., Calbet-llopart, N., Combalia, M., Tell-Martí, G., Puig-Butille, J.A., Barreiro, A., Podlipnik, S., Carrera, C., Malvehy, J., Puig, S.

“…Melanoma is the most aggressive of common skin cancers. We aimed to create a polygenic risk score (PRS) and evaluate its capability to predict melanoma…”
Get full text